Pediatrix Medical Group Reports Second Quarter Results

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Negative)

Insights

Pediatrix's Q2 2024 results present a mixed picture. The company reported a loss of $1.84 per share, but Adjusted EPS of $0.34. Revenue increased slightly to $504 million, with same-unit revenue growth of 2.8%. The net loss of $153 million is concerning, largely due to a $192.9 million non-cash impairment loss.

Positively, the company saw improved payor mix and operating efficiencies. The 2.4% increase in same-unit revenue from reimbursement factors is encouraging. However, patient volume growth was minimal at 0.4%.

The ongoing portfolio management plan, including exiting office-based practices, could improve profitability. The expected $30 million annual boost to Adjusted EBITDA from this plan could be significant for future performance.

Pediatrix's strategic shift towards hospital-based care and maternal-fetal medicine is noteworthy. This focus aligns with industry trends favoring specialized, high-acuity services. The decision to exit almost all office-based practices (except maternal-fetal medicine) and the primary/urgent care service line is a significant transformation.

The stable NICU days (-0.8% for Q2, +0.9% YTD) suggest resilience in their core neonatology services. The improved payor mix, with a 230 basis point increase in commercial and non-government payors, is a positive indicator for future revenue stability.

The transition in leadership, particularly the CFO change and the creation of a Chief Administrative Officer role, signals a commitment to navigating this strategic shift effectively. However, investors should monitor how these changes impact operational execution in the short term.

Pediatrix's Q2 results and strategic shifts reflect broader healthcare market trends. The focus on hospital-based services and maternal-fetal medicine aligns with the industry's move towards specialized, high-value care. This could position Pediatrix favorably in a competitive landscape.

The improved payor mix is particularly significant, indicating better negotiating power or a shift in patient demographics. This could lead to more stable, potentially higher revenues per patient.

The company's portfolio management plan, while disruptive in the short term, appears to be a proactive response to market pressures. Exiting lower-margin services to focus on core competencies is a strategy we're seeing across the healthcare sector. The projected $30 million boost to Adjusted EBITDA suggests this move could significantly improve Pediatrix's financial health and market position in the long run.

08/06/2024 - 06:00 AM

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today reported a loss of $1.84 per share for the three months ended June 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.34.

For the 2024 second quarter, Pediatrix reported the following results:

Net revenue of $504 million;
Net loss of $153 million; and
Adjusted EBITDA of $58 million.

“Our second quarter operating results exceeded our expectations and reflected stable patient volumes, improved payor mix, and operating efficiencies,” said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. “Our previously discussed portfolio management plans are well underway and we expect to complete these plans by the end of 2024. We believe that these operating plans, our strengthening financial position, and our focus on hospital-based care and maternal-fetal medicine will benefit all of our stakeholders.”

Operating Results–Three Months Ended June 30, 2024

Pediatrix’s net revenue for the three months ended June 30, 2024 was $504.3 million, compared to $500.6 million for the prior-year period. This increase reflected growth in same-unit revenue of 2.8 percent, partially offset by the impact of non-same unit activity, primarily practice dispositions.

Same-unit revenue from net reimbursement-related factors increased by 2.4 percent for the 2024 second quarter as compared to the prior-year period. This increase primarily reflects improved payor mix and modest improvements in hospital contract administrative fees. The percentage of services reimbursed by commercial and other non-government payors increased by approximately 230 basis points compared to the prior year period.

Same-unit revenue attributable to patient volume increased by 0.4 percent for the 2024 second quarter as compared to the prior-year period. Shown below are year-over-year percentage changes in certain same-unit volume statistics for the three and six months ended June 30, 2024. (Note: figures in the below table reflect contributions only to net patient service revenue and exclude other contributions to total same-unit revenue, including contract and administrative fees.)

	Three Months Ended June 30, 2024	Six Months Ended June 30, 2024

Hospital-based patient services	1.0%	1.7%
Office-based patient services	(1.2)%	0.7%

Neonatology services (within hospital-based services):
Neonatal intensive care unit (NICU) days	(0.8)%	0.9%

For the 2024 second quarter, practice salaries and benefits expense was $357.8 million, compared to $354.0 million for the prior-year period. This comparison primarily reflects increases in same-unit clinical compensation costs, partially offset by the impact of non-same unit activity, primarily practice dispositions.

For the 2024 second quarter, general and administrative expenses were $56.6 million, as compared to $58.0 million for the prior-year period. This decline primarily reflects net staffing reductions that more than offset increased internal staffing as part of the Company’s ongoing development of its hybrid revenue cycle management structure.

For 2024 second quarter, transformational and restructuring related expenses totaled $13.6 million. These expenses related primarily to practice dispositions and revenue cycle management transition activities.

Adjusted EBITDA, which is defined as earnings before interest, taxes, depreciation and amortization, transformational and restructuring related expenses, and loss on disposal of businesses and impairment losses, was $57.9 million for the 2024 second quarter, compared to $59.1 million for the prior-year period.

Depreciation and amortization expense was $8.8 million for the second quarter of 2024, compared to $8.9 million for the prior-year period.

Interest expense was $10.3 million for the second quarter of 2024, compared to $11.2 million for the second quarter of 2023, reflecting lower outstanding borrowings.

During the second quarter of 2024, the Company recorded an aggregate non-cash impairment loss of $192.9 million related to goodwill and long-lived assets related to the Company’s portfolio management plan.

Pediatrix generated a net loss of $153.0 million, or $1.84 per diluted share, for the 2024 second quarter, based on a weighted average 83.3 million shares outstanding. This compares with net income of $28.3 million, or $0.34 per diluted share, for the 2023 second quarter, based on a weighted average 82.7 million shares outstanding.

For the second quarter of 2024, Pediatrix reported Adjusted EPS of $0.34, compared to $0.39 for the second quarter of 2023. For these periods, Adjusted EPS is defined as diluted income per common and common equivalent share excluding non-cash amortization expense, stock-based compensation expense, transformational and restructuring related expenses, loss on disposal of businesses and impairment losses, and discrete tax events.

Operating Results – Six Months Ended June 30, 2024

For the six months ended June 30, 2024, Pediatrix generated revenue of $999.4 million, compared to $991.6 million for the prior-year period. Pediatrix generated a net loss of $149.0 million, or $1.79 per share, for the six months ended June 30, 2024, based on a weighted average 83.1 million shares outstanding, which compares to income of $42.5 million, or $0.52 per share, based on a weighted average 82.4 million shares outstanding for the first six months of 2023. Adjusted EBITDA for the six months ended June 30, 2024 was $95.1 million, compared to $99.2 million for the prior year. For the six months ended June 30, 2024, Pediatrix reported Adjusted EPS of $0.54, compared to $0.62 in the same period of 2023.

Financial Position and Cash Flow – Continuing Operations

Pediatrix had cash and cash equivalents of $19.4 million at June 30, 2024, compared to $73.3 million on December 31, 2023, and net accounts receivable were $274.2 million.

For the second quarter of 2024, Pediatrix generated cash from continuing operations of $109.3 million, compared to $92.6 million during the second quarter of 2023. During the second quarter of 2024, the Company used $7.0 million to fund capital expenditures.

At June 30, 2024, Pediatrix had total debt outstanding of $622 million, consisting of its $400 million in 5.375% Senior Notes due 2030 and $222 million in borrowings under its Term A Loan. At June 30, 2024, the Company had no outstanding borrowings under its $450 million revolving line of credit.

Portfolio Management Update

As previously disclosed, during the second quarter of 2024, Pediatrix formalized its practice portfolio management plans, resulting in a decision to exit almost all of its affiliated office-based practices, other than maternal-fetal medicine. The Company expects to complete these exits prior to the end of 2024. In addition, Pediatrix previously disclosed its intent to exit its primary and urgent care service line. During and subsequent to the end of the 2024 second quarter, the Company completed the exit of its primary and urgent care service line through two separate transactions.

In aggregate, the office-based practices that the Company intends to exit and the primary and urgent care clinics that have been divested contributed net revenue of approximately $200 million in 2023. As previously disclosed, Pediatrix expects that the annualized favorable impact to Adjusted EBITDA resulting from its portfolio management plans to be approximately $30 million.

Leadership Transitions

Chief Financial Officer Transition

Pediatrix announced today that its board of directors has appointed Ms. Kasandra Rossi, who currently serves as the Company’s Senior Vice President, Financial Reporting and Assistant Treasurer, to succeed Mr. C. Marc Richards as Executive Vice President, Chief Financial Officer and Treasurer of the Company. The transition will be effective on or about October 1, 2024, following the anticipated completion of the next phase of the Company’s previously announced transition of its outsourced enterprise revenue cycle management services and the advancement of the Company’s planned portfolio management activities.

Chief Administrative Officer Appointment

The Company also announced today that its board of directors has appointed Ms. Mary Ann E. Moore to serve as the Company’s Chief Administrative Officer, in addition to her existing roles as the Company’s Executive Vice President, General Counsel and Secretary, effective as of August 1, 2024.

In addition, Pediatrix announced that Curtis B. Pickert, M.D. has transitioned from his role as the Company’s Executive Vice President, Chief Operating Officer and will now serve as Pediatrix’s Executive Vice President, Chief Physician Executive, effective as of August 1, 2024.

2024 Outlook

As previously disclosed, Pediatrix anticipates that its 2024 Adjusted EBITDA, as defined below, will be in a range of $200 million to $220 million.

Non-GAAP Measures

A reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable GAAP measures for the three and six months ended June 30, 2024 and 2023 is provided in the financial tables of this press release.

Earnings Conference Call

Pediatrix will host an investor conference call to discuss the quarterly results at 9 a.m., ET today. The conference call Webcast may be accessed from the Company’s Website, www.pediatrix.com. A telephone replay of the conference call will be available from 12:45 p.m. ET today through midnight ET August 20, 2024 by dialing 1-866-207-1041, access code 7909485. The replay will also be available at www.pediatrix.com.

ABOUT PEDIATRIX MEDICAL GROUP

Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through more than 5,000 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn, Twitter and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors.

Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company’s objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well the Company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the Company’s practice portfolio management plans and whether the Company is able to achieve the expected favorable impact to Adjusted EBITDA therefrom; the impact of the Company’s termination of its then third-party revenue cycle management provider and transition to a hybrid revenue cycle management model with one or more new third-party service providers, including any transition costs associated therewith; the impact of surprise billing legislation; the effects of economic conditions on the Company’s business; the effects of the Affordable Care Act and potential healthcare reform; the Company’s relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the Company’s ability to comply with the terms of its debt financing arrangements; the impact of the COVID-19 pandemic on the Company and its financial condition and results of operations; the impact of the divestiture of the Company’s anesthesiology and radiology medical groups; the impact of management transitions; the timing and contribution of future acquisitions or organic growth initiatives; the effects of share repurchases; and the effects of the Company’s transformation initiatives, including its reorientation on, and growth strategy for, its pediatrics and obstetrics business.

Pediatrix Medical Group, Inc. Consolidated Statements of Income and Comprehensive Income (in thousands, except per share data) (Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2024			2023			2024			2023
Net revenue	$	504,296		$	500,577		$	999,397		$	991,585
Operating expenses:
Practice salaries and benefits		357,808			354,032			726,946			716,267
Practice supplies and other operating expenses		32,369			31,089			63,454			61,809
General and administrative expenses		56,565			58,013			116,763			117,072
Depreciation and amortization		8,791			8,945			19,099			17,898
Transformational and restructuring related expenses		13,579			—			22,059			—
Goodwill impairment		154,243			—			154,243			—
Fixed assets impairments		20,112			—			20,112			—
Intangible assets impairments		7,679			—			7,679			—
Loss on disposal of businesses		10,873			—			10,873			—
Total operating expenses		662,019			452,079			1,141,228			913,046
(Loss) income from operations		(157,723	)		48,498			(141,831	)		78,539
Investment and other (loss) income		(161	)		1,189			1,852			1,823
Interest expense		(10,308	)		(11,230	)		(20,907	)		(21,620	)
Equity in earnings of unconsolidated affiliate		464			490			982			917
Total non-operating expenses		(10,005	)		(9,551	)		(18,073	)		(18,880	)
(Loss) income before income taxes		(167,728	)		38,947			(159,904	)		59,659
Income tax benefit (provision)		14,703			(10,665	)		10,914			(17,171	)
Net (loss) income	$	(153,025	)	$	28,282		$	(148,990	)	$	42,488
Other comprehensive (loss) income, net of tax
Unrealized holding gain (loss) on investments, net of tax of $66, $126, $86 and $353		200			(387	)		260			217
Total comprehensive (loss) income	$	(152,825	)	$	27,895		$	(148,730	)	$	42,705
Per common and common equivalent share data (diluted):
Net (loss) income:	$	(1.84	)	$	0.34		$	(1.79	)	$	0.52
Weighted average common shares		83,332			82,664			83,074			82,377

Pediatrix Medical Group, Inc. Reconciliation of Net (Loss) Income to Adjusted EBITDA (in thousands) (Unaudited)

	Three Months Ended June 30,					Six Months Ended June 30,
	2024			2023		2024			2023
Net (loss) income	$	(153,025	)	$	28,282	$	(148,990	)	$	42,488
Interest expense		10,308			11,230		20,907			21,620
Income tax (benefit) provision		(14,703	)		10,665		(10,914	)		17,171
Depreciation and amortization expense		8,791			8,945		19,099			17,898
Transformational and restructuring related expenses		13,579			—		22,059			—
Goodwill impairment		154,243			—		154,243			—
Fixed assets impairments		20,112			—		20,112			—
Intangible assets impairments		7,679			—		7,679			—
Loss on disposal of businesses		10,873			—		10,873			—
Adjusted EBITDA	$	57,857		$	59,122	$	95,068		$	99,177

Pediatrix Medical Group, Inc. Reconciliation of Diluted Net Income per Share to Adjusted (Loss) Income per Diluted Share (“Adjusted EPS”) (in thousands, except per share data) (Unaudited)

	Three Months Ended June 30,
	2024						2023
Weighted average diluted shares outstanding	83,332						82,664
Net (loss) income and diluted net (loss) income per share	$	(153,025	)	$	(1.84	)	$	28,282	$	0.34
Adjustments ⁽¹⁾:
Amortization (net of tax of $533 and $512)		1,599			0.02			1,533		0.02
Stock-based compensation (net of tax of $500 and $782)		1,501			0.02			2,344		0.03
Transformational and restructuring expenses (net of tax of $3,395)		10,184			0.12			—		—
Goodwill impairment (net of tax of $15,490)		138,753			1.67			—		—
Fixed assets impairments (net of tax of $5,028)		15,084			0.18			—		—
Intangible assets impairments (net of tax of $1,920)		5,759			0.07			—		—
Loss on disposal of businesses (net of tax of $2,718)		8,155			0.10			—		—
Net impact from discrete tax events		328			—			150		—
Adjusted income and diluted EPS	$	28,338		$	0.34		$	32,309	$	0.39

(1) A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the three months ended June 30, 2024 and 2023, other than for goodwill impairment for the relevant period. Tax effects for the goodwill impairment approximate 10% due to a portion of the expense being non-deductible.

	Six Months Ended June 30,
	2024						2023
Weighted average diluted shares outstanding	83,074						82,377
Net (loss) income and diluted net (loss) income per share	$	(148,990	)	$	(1.79	)	$	42,488	$	0.52
Adjustments ⁽¹⁾:
Amortization (net of tax of $1,396 and $1,010)		4,188			0.05			3,029		0.04
Stock-based compensation (net of tax of $1,215 and $1,534)		3,647			0.04			4,601		0.06
Transformational and restructuring expenses (net of tax of $5,515)		16,544			0.20			—		—
Goodwill impairment (net of tax of $15,490)		138,753			1.67			—		—
Fixed assets impairments (net of tax of $5,028)		15,084			0.18			—		—
Intangible assets impairments (net of tax of $1,920)		5,759			0.07			—		—
Loss on disposal of businesses (net of tax of $2,718)		8,155			0.10			—		—
Net impact from discrete tax events		2,004			0.02			870		—
Adjusted income and diluted EPS	$	45,144		$	0.54		$	50,988	$	0.62

(1) A blended tax rate of 25% was used to calculate the tax effects of the adjustments for the six months ended June 30, 2024 and 2023, other than for goodwill impairment for the relevant period. Tax effects for the goodwill impairment approximate 10% due to a portion of the expense being non-deductible.

Pediatrix Medical Group, Inc. Balance Sheet Highlights (in thousands) (Unaudited)

	As of June 30, 2024		As of December 31, 2023
Assets:
Cash and cash equivalents	$	19,402	$	73,258
Investments		113,795		104,485
Accounts receivable, net		274,164		272,313
Other current assets		21,851		33,398
Intangible assets, net		10,193		21,240
Operating and finance lease right-of-use assets		65,392		70,294
Goodwill, other assets, property and equipment		1,490,554		1,644,822
Total assets	$	1,995,351	$	2,219,810
Liabilities and shareholders' equity:
Accounts payable and accrued expenses	$	267,333	$	350,798
Total debt, including finance leases, net		630,370		633,334
Operating lease liabilities		67,940		68,314
Other liabilities		323,247		318,303
Total liabilities		1,288,890		1,370,749
Total shareholders' equity		706,461		849,061
Total liabilities and shareholders' equity	$	1,995,351	$	2,219,810

Pediatrix Medical Group, Inc. Reconciliation of Net Loss to Forward-Looking Adjusted EBITDA (in thousands) (Unaudited)

	Year Ended December 31, 2024

Net loss	$	(112,507	)	$	(97,907	)
Interest expense		40,020			40,020
Income tax provision		2,580			7,980
Depreciation and amortization expense		37,000			37,000
Transformational and restructuring related expenses		40,000			40,000
Goodwill and long-lived asset impairments		182,034			182,034
Loss on disposal of businesses		10,873			10,873
Adjusted EBITDA	$	200,000		$	220,000

View source version on businesswire.com: https://www.businesswire.com/news/home/20240806739762/en/

Charles Lynch

Senior Vice President, Finance and Strategy

954-384-0175, x 5692

charles.lynch@pediatrix.com

Source: Pediatrix Medical Group, Inc.

FAQ

What was Pediatrix Medical Group's (MD) revenue for Q2 2024?

Pediatrix Medical Group reported net revenue of $504.3 million for Q2 2024, compared to $500.6 million for the prior-year period.

How did Pediatrix's (MD) same-unit revenue perform in Q2 2024?

Pediatrix's same-unit revenue grew by 2.8% in Q2 2024, with a 2.4% increase from net reimbursement-related factors and a 0.4% increase attributable to patient volume.

What is Pediatrix Medical Group's (MD) Adjusted EBITDA outlook for 2024?

Pediatrix Medical Group maintains its 2024 Adjusted EBITDA outlook in the range of $200 million to $220 million.

How much debt did Pediatrix Medical Group (MD) have as of June 30, 2024?

As of June 30, 2024, Pediatrix Medical Group had total debt outstanding of $622 million, consisting of $400 million in Senior Notes and $222 million in Term A Loan borrowings.

Pediatrix Medical Group Reports Second Quarter Results

Insights

FAQ

What was Pediatrix Medical Group's (MD) revenue for Q2 2024?

How did Pediatrix's (MD) same-unit revenue perform in Q2 2024?

What is Pediatrix Medical Group's (MD) Adjusted EBITDA outlook for 2024?

How much debt did Pediatrix Medical Group (MD) have as of June 30, 2024?

NYSE:MD

MD Rankings

MD Latest News

MD Stock Data

Trending News

Pediatrix Medical Group Reports Second Quarter Results

Insights

Financial Analyst neutral

Healthcare Industry Analyst neutral

Market Research Analyst neutral

FAQ

What was Pediatrix Medical Group's (MD) revenue for Q2 2024?

How did Pediatrix's (MD) same-unit revenue perform in Q2 2024?

What is Pediatrix Medical Group's (MD) Adjusted EBITDA outlook for 2024?

How much debt did Pediatrix Medical Group (MD) have as of June 30, 2024?

NYSE:MD

MD Rankings

MD Latest News

MD Stock Data